Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis.

ABSTRACT:

Importance

Since the increased use of dupilumab for atopic dermatitis (AD) in daily practice, several cases have been reported on the development of cutaneous T-cell lymphomas (CTCL) and lymphoid infiltrates.

Objective

To provide insight in the clinical and histopathologic features of patients with AD clinically suspected for CTCL during dupilumab treatment.

Design, setting, and participants

This retrospective observational case series included adult (≥18 years) patients with AD treated with dupilumab between October 2017 and July 2022 at the University Medical Center Utrecht in the Netherlands.

Main outcomes and measures

Relevant patient, disease, and treatment characteristics were evaluated. Skin biopsies before, during, and after treatment were collected and

SUBMITTER: Boesjes CM 

PROVIDER: S-EPMC10585590 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature